Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tsuranobu Shirahama is active.

Publication


Featured researches published by Tsuranobu Shirahama.


Biochemical and Biophysical Research Communications | 1985

A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin

Fumitake Gejyo; Takahisa Yamada; Shoji Odani; Yoichi Nakagawa; Masaaki Arakawa; Tetsunosuke Kunitomo; H. Kataoka; M. Suzuki; Y. Hirasawa; Tsuranobu Shirahama; A. S. Cohen; Karl Schmid

Amyloid fibrils were isolated from amyloid-laden tissue obtained from a chronic hemodialysis patient with carpal tunnel syndrome. After solubilization in guanidine HCl, a significant amount of the protein was located in a homogeneous low molecular weight fraction. The protein was found to be identical to beta 2-microglobulin, with regard to its molecular weight of 11,000, amino acid composition and 16 amino-terminal amino acids: Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-. These results demonstrate that the amyloid associated with chronic hemodialysis contains as major component a new form of amyloid fibril protein that is homologous to beta 2-microglobulin.


Biochemical and Biophysical Research Communications | 1985

In vitro formation of amyloid fibrils from intact β2-microglobulin

Lawreen H. Connors; Tsuranobu Shirahama; Martha Skinner; A. Fenves; A. S. Cohen

Prompted by the identification of hemodialysis-associated amyloid protein as beta 2-microglobulin, we attempted to create in vitro amyloid fibrils from the native protein. Beta 2-microglobulin in PBS was slowly dialyzed free of salt and then concentrated. The residue showed Congophilia with green birefringence by light microscopy and polarization, and non-branching fibrils of indeterminate length, measuring 8 to 10 nm in diameter by electron microscopy, thus meeting the morphologic criteria for amyloid. The present study demonstrates the first successful in vitro creation of amyloid fibrils with intact precursor protein molecules and provides supporting evidence that hemodialysis-associated amyloid is constituted from beta 2-microglobulin.


The American Journal of Medicine | 1987

Hemodialysis-associated amyloidosis and beta-2 microglobulin: Clinical and immunohistochemical study

Thomas Bardin; Johanna Zingraff; Tsuranobu Shirahama; Laure-Hélène Noël; Dominique Droz; Marie-Catherine Voisin; Tilman B. Drüeke; Antoine Dryll; Martha Skinner; Alan S. Cohen; Daniel Kuntz

The beta-2 microglobulin type of amyloidosis was identified in articular and para-articular tissues of 14 patients with non-amyloid nephropathies undergoing long-term hemodialysis. Ten patients had carpal tunnel syndrome, 13 had juxta-articular radiolucent cysts (complicated by spontaneous fractures of the femoral neck in three), and six had destructive arthropathies of the large joints of the limbs. Massive amyloid deposits were found in the synovium, capsule, ligaments, articular cartilage, and/or bone. They were characterized by Congo red-induced green birefringence that was sensitive to potassium permanganate treatment. They reacted with anti-beta-2 microglobulin antiserum, whereas they did not react with antibodies directed against AA protein, prealbumin, or immunoglobulins. These data suggest that the potentially disabling arthropathy of hemodialysis is due to amyloid lesions. The persistently elevated plasma beta-2 microglobulin levels may play a role in the pathogenesis of this recently recognized complication, and if so, this complication should be preventable.


The American Journal of Medicine | 1987

Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience

Margaret A. Duston; Martha Skinner; Tsuranobu Shirahama; Alan S. Cohen

Abdominal fat aspiration samples from 443 consecutive patients were examined for amyloid after Congo red and hematoxylin staining. Of the aspirates from 83 patients known to have systemic amyloid disease prior to the biopsy, 70 (84 percent) were found to yield positive results. The results for four aspirates from patients with localized amyloid disease were negative. Of the aspirates from 356 patients of unknown clinical status referred for analysis by outside physicians, 26 (7 percent) yielded positive results for amyloid. On review of the clinical records of these 26 patients, 11 had proved systemic amyloidosis demonstrated on biopsy of another site; all had a clinical course consistent with amyloid disease. In no case was amyloid found in a fat aspiration sample from a patient without clinical evidence suggestive of systemic amyloid disease. This study supports the proposal that abdominal fat aspiration is the diagnostic procedure of choice in the evaluation of amyloidosis since it requires no specialty consultation or technical expertise, causes minimal patient discomfort, and is accompanied by virtually no risk of morbid complication. A positive result has a high predictive value of amyloid disease in patients of unknown clinical status.


Preparative Biochemistry & Biotechnology | 1982

The association of amyloid P-component (AP) with the amyloid fibril: An updated method for amyloid fibril protein isolation

Martha Skinner; Tsuranobu Shirahama; Alan S. Cohen; Chad L. Deal

An amyloid fibril isolation procedure is proposed which uses citrate as well as saline washes to dissociate the calcium dependent linkage of amyloid P-component (AP) from the amyloid fibril. In two amyloid rich tissues, the amount of AP was quantitated in each saline and citrate wash and totalled 13.8% and 20.8% of the amyloid fibrils isolated. The amount of AP removed from these and 22 additional amyloid rich tissues was greater than had previously been recognized. AP protein was present in tissue only when amyloid fibrils were present. It could not be found in normal non-amyloidotic tissue, nor could it be found in tissue sediment after the fibrils were removed.


Journal of Clinical Investigation | 1977

Kinetics of serum amyloid protein A in casein-induced murine amyloidosis.

Merrill D. Benson; Morton Scheinberg; Tsuranobu Shirahama; Edgar S. Cathcart; Martha Skinner

Serum amyloid protein A (SAA), the precursor of secondary amyloid protein, is elevated in chronic diseases which are associated with an increased incidence of amyloid. However, SAA is also elevated in acute bacterial and viral infections and somes forms of cancer. The murine model of casein-induced amyloidosis was studied to determine the relationship between SAA production and amyloid deposition. SAA levels measured by radioimmunoassay were found to be as high as 200 times the normal level in CBA/J mice receiving daily parenteral casein. After a single injection of casein the SAA level was elevated by 3h and peaked by 12-18 h. Similar levels were found in casein-treated A/J mice, a strain less susceptible to the induction of amyloid. Parenterally administered bovine serum albumin, which has low potential for amyloid induction, gave SAA levels in CBA/J and A/J mice comparable to casein treatment. These data show that, while SAA levels are elevated during chronic antigenic stimulation, there are other factors involved in amyloid formation. These factors may include alterations in the degradation of SAA by the reticuloendothelial system caused by substances such as casein. Nude (athymic) mice were shown to attain high levels of SAA after receiving casein parenterally. Therefore, thymus-derived lymphocytes are not necessary for the synthesis of SAA.


Virchows Archiv B Cell Pathology Including Molecular Pathology | 1986

The induction of accelerated murine amyloid with human splenic extract - Probable role of amyloid enhancing factor

John Varga; Margaret S.M. Flinn; Tsuranobu Shirahama; Orville G. Rodgers; Alan S. Cohen

SummaryAmyloid enhancing factor (AEF) is derived from the tissues of pre-amyloidotic and amyloidotic animals and, when transfered, greatly accelerates amyloid induction in the recipient murine models. It has also been reported that similarly accelerated amyloid induction can be achieved in mice by injection of human splenic homogenates from patients with amyloidosis. The present study has attempted to characterize further the mechanism of this “heterologous transfer of amyloid”. Treatment of mice with the “tissue homogenate” or the “AEF extract” of AA-, AL-and Aprealbumin-laden human spleens followed by daily subcutaneous casein injections induced amyloidosis in an accelerated fashion. The resultant amyloid deposits in mice had strongly positive immunohistochemical reactions with anti-mouse AA, and negative reaction with anti-human AA or anti-human prealbumin. The results lend support to the idea that accelerated amyloid induction in the recipient mice is unlikely to be due to transfer of human amyloid substance, but rather to formation of “native” murine amyloid under the influence of a human AEF factor similar to or identical with AEF described in mouse-to mouse transfer models.


Histochemistry and Cell Biology | 1981

Immunocytochemical identification of amyloid in formalin-fixed paraffin sections

Tsuranobu Shirahama; Martha Skinner; A. S. Cohen

SummaryFormalin-fixed paraffin sections of livers, spleens and kidneys from patients with primary, secondary and familial amyloidosis as well as from a casein-induced murine amyloid model were analysed by an immunocy-tochemical (unlabeled antibody enzyme) method utilizing antisera to amyloid-related proteins. All amyloid deposits of all amyloid types showed positive reactions with anti-AP of the respective species. Positive reaction of anti-human AA to human secondary amyloid deposits and of anti-mouse AA to the deposits of casein-induced murine amyloid was also observed, but there was no species cross reactivity. No significant deposition of the reaction products was produced by anti-immunoglobulin light chains on deposits of any amyloid type, or by anti-AA in the tissues from primary or familial amyloidosis. The results indicate that amyloid proteins AA and AP can survive as antigens through routine histologic preparation, that anti-AP can be a universal marker for deposits of any amyloid type within the same species, and that AA-type amyloid can be identified by this method while there may as yet be no feasible universal marker for the AL-type at present.


The American Journal of Medicine | 1984

Familial amyloid polyneuropathy. Demonstration of prealbumin in a kinship of german/english ancestry with onset in the seventh decade

Caryn A. Libbey; Alan Rubinow; Tsuranobu Shirahama; Chad L. Deal; Alan S. Cohen

A family with autosomal dominant transmitted familial amyloid polyneuropathy residing in Texas is described. Clinically, the prominent sensory and severe autonomic nervous system involvement resembles the Andrade (Portuguese) type I familial amyloid polyneuropathy but is unique in that the age of onset is in the seventh decade in all family members affected to date. Using an immunoperoxidase technique, prealbumin was demonstrated in the amyloid deposits. This finding suggests that this family shares biochemical as well as clinical characteristics consistent with similar kinships with type I familial amyloid polyneuropathy of diverse geographic origin.


Experimental Biology and Medicine | 1969

Heterologous transfer of amyloid--human to mouse.

Tsuranobu Shirahama; Oliver J. Lawless; Alan S. Cohen

Summary Intraperitoneal administration of human amyloid spleen homogenate together with casein caused amyloidosis in recipient C3H mice within 5 days. The results suggest the existence of a factor accelerating induction of amyloidosis that is active across histocompatibility barriers and provide a simpler model without immunosuppressive agents for further investigations of this transfer factor.

Collaboration


Dive into the Tsuranobu Shirahama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean D. Sipe

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge